Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New cachexic factors.

M J Tisdale1

  • 1Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.

Current Opinion in Clinical Nutrition and Metabolic Care
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Cancer cachexia involves significant weight and muscle loss. A urinary glycoprotein directly causes muscle protein breakdown, and its effects can be counteracted by agents like eicosapentaenoic acid, offering a promising treatment avenue.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia.

The Journal of frailty & aging·2016
Same author

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

British journal of cancer·2014
Same author

Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.

Cellular signalling·2012
Same author

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

British journal of cancer·2011
Same author

Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat.

International journal of obesity (2005)·2010
Same author

Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse.

International journal of obesity (2005)·2010
Same journal

Seeing cachexia clearly: the evolution of body composition and radiological biomarkers in cancer wasting.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

The updated recommendations for medical nutrition in the perioperative period: a focus on early oral intake.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Pediatric and adolescent nutritional and metabolic assessment in the precision era.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Nutrition in cirrhosis: bridging guidelines and practice in hepatic disease.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Metabolic health in a changing world: widening the lens to climate, cities, and place.

Current opinion in clinical nutrition and metabolic care·2026
Same journal

Beyond the scale: a systems-level reframing of obesity and metabolic care.

Current opinion in clinical nutrition and metabolic care·2026
See all related articles

Area of Science:

  • Oncology
  • Metabolic Research
  • Biochemistry

Background:

  • Cancer cachexia, characterized by adipose and lean body mass loss, is prevalent at diagnosis.
  • Cytokines are implicated in cachexia, but human evidence is limited, with IL-6 only correlating, not mediating.
  • Existing treatments like nutritional manipulation show limited success.

Purpose of the Study:

  • To investigate the mechanisms underlying cancer cachexia.
  • To identify potential therapeutic targets for managing cachexia.

Main Methods:

  • Analysis of patient samples and experimental models.
  • Investigation of cytokine involvement and molecular pathways.
  • Testing of pharmacological agents for cachexia treatment.

Related Experiment Videos

Main Results:

  • A urinary sulphated glycoprotein directly induces skeletal muscle protein catabolism via prostaglandin E2.
  • Agents like eicosapentaenoic acid and ibuprofen attenuated this effect.
  • Pharmacological interventions stabilized weight loss in cachectic patients.

Conclusions:

  • Cancer cachexia involves a direct catabolic mechanism mediated by a urinary glycoprotein.
  • Pharmacological approaches targeting this mechanism show promise for treating cachexia.
  • This approach appears more effective than nutritional interventions.